Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Genetic Technologies's Sloan Ratio for the quarter that ended in Dec. 2023 was 97.02%.
As of Dec. 2023, Genetic Technologies has a Sloan Ratio of 97.02%, indicating there is a warning stage of accrual build up.
Genetic Technologies Sloan Ratio % Historical Data
The historical data trend for Genetic Technologies's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genetic Technologies's Sloan Ratio %
For the Diagnostics & Research subindustry, Genetic Technologies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's Sloan Ratio % falls into.
Genetic Technologies Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Genetic Technologies's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as
Genetic Technologies's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = $0.00 Mil.
Genetic Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -0.687 (Mar. 2023 ) + -2.074 (Jun. 2023 ) + -1.888 (Sep. 2023 ) + -0.719 (Dec. 2023 ) = $-5.37 Mil.
Genetic Technologies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.001 (Mar. 2023 ) + -0.19 (Jun. 2023 ) + -0.013 (Sep. 2023 ) + 0.074 (Dec. 2023 ) = $-0.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Technologies (NAS:GENE) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, Genetic Technologies has a Sloan Ratio of 97.02%, indicating there is a warning stage of accrual build up.
Genetic Technologies Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Genetic Technologies's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Genetic Technologies (Genetic Technologies) Business Description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GENE has been successfully added to your 